Hepion Pharmaceuticals, Inc.

Equities

HEPA

US4268973025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-16 EDT			5-day change	1st Jan Change
1.08 ^USD	+5.88%		+3.85%	-66.67%

05-21	Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-22	Sector Update: Health Care Stocks Increase Late Afternoon	MT

HEPION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 05, 2021 at 09:38 am

Item 8.01 Other Events

On January 5, 2021, Hepion Pharmaceuticals, Inc. (the "Company") issued a press release announcing that management will participate in two virtual investor conferences in January. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits






(d) Exhibits

99.1 Hepion Pharmaceuticals, Inc. Press Release dated January 5, 2021

Latest news about Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-21	CI
Sector Update: Health Care Stocks Increase Late Afternoon	04-22	MT
Sector Update: Health Care	04-22	MT
Top Midday Decliners	04-22	MT
North American Morning Briefing: Stock Futures Rise, Busy Week of Earnings Ahead	04-22	DJ
Hepion Pharmaceuticals Starts Wind-Down Activities in Phase 2b ASCEND-NASH Trial	04-19	MT
Hepion Pharmaceuticals, Inc. Initiates Wind-Down Activities in Phase 2b ?ASCEND-NASH? Trial	04-19	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Hepion Pharmaceuticals, Inc. Appoints Michael Purcell to Its Board of Directors	03-06	CI
Hepion Pharmaceuticals, Inc. Announces Board Changes	02-20	CI
Hepion Pharmaceuticals, Inc. Announces Resignation of Anand Reddi from the Board of Directors	02-07	CI
North American Morning Briefing : Futures Pause -2-	12-08	DJ
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value	12-07	CI
Hepion Pharmaceuticals Approves Restructuring Plan to Preserve Capital, Launches Strategic Review Process	12-07	MT
Hepion Pharmaceuticals, Inc. Announces Resignation of Robert Foster as Director	12-07	CI
Hepion Pharmaceuticals, Inc. Announces CEO Changes	12-07	CI
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase 2 Study of Advanced (F3) Mash Liver Disease	11-13	CI
Hepion Pharmaceuticals, Inc. Announces the Publication of New Research Study in Mice	23-10-25	CI
Hepion Pharmaceuticals, Inc. announced that it has received $5.000004 million in funding	23-10-02	CI
Hepion Pharmaceuticals, Inc. announced that it expects to receive $5.000004 million in funding	23-09-27	CI
Hepion Pharmaceuticals, Inc. Announces Results from A Study with in Which the Anti-Cancer Activity of Hepion's Lead Drug Candidate, Rencofilstat	23-09-21	CI
Aurinia Pharmaceuticals Appoints Robert Foster as Part of Deal With Shareholder MKT Capital	23-09-21	MT
Hepion Pharmaceuticals Reports Novel Rencofilstat Action in Liver Cancer	23-09-19	MT
Hepion Says Research Study on Idiopathic Pulmonary Fibrosis Involving Drug Candidate Rencofilstat Showed Positive Results	23-09-14	MT

Chart Hepion Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
HEPION PHARMACEUTICALS, INC.	-66.67%	5.58M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs